It has also become evident that in several lymphoma types such as follicular lymphoma and CLL, adding PDL1 blockers to conventional therapy regimens shows a benefit in comparison to only very limited treatment response if given as single agents (72). The gene discussed is CD274; the disease is lymphoma.